Pfizer Launches Consumer Access Program for Vaccines and Some Medications

Pfizer has introduced a direct-to-consumer platform for adults with migraine or who are looking for vaccines for COVID-19, flu, RSV and pneumococcal pneumonia. Through the platform, called PfizerForAll, patients will be able to connect with a healthcare professional, find and book vaccines, receive tests and medications at home or via a preferred pharmacy, and find savings and support.

Aamir Malik

“People often experience information overload and encounter roadblocks when making decisions for themselves or their family in our complex and often overwhelming U.S. healthcare system. This can be extremely time-consuming and lead to indecision or inaction – and as a result, poor health outcomes,” Aamir Malik, executive vice president, chief U.S. commercial officer at Pfizer, said in a news release.

Pfizer is partnering with several organizations — including the telemedicine company UpScriptHealth, Alto Pharmacy and Instacart — to develop PfizerForAll. Patients will be able to use existing insurance and pharmacy programs.

PfizerForAll puts Pfizer’s savings and support solutions in one place, including co-pay cards and patient support and access services. Patients can also access information to assist with navigating the insurance process for those prescribed migraine and COVID-19 treatments.

Patients with COVID-19 or the flu can a set up a virtual appointment with a doctor through UpScript for $35 or order at-home tests through Instacart.

Related: FDA Grants Approvals for Two Updated COVID-19 Vaccines

Last week, Pfizer received approved for its updated COVID-19 vaccine with the Omicron variant KP.2 strain of SARS-CoV-2, which the FDA indicates is the preferred strain for the 2024-2025 fall and winter season.

Pfizer also markets Paxlovid (nirmatrelvir/ritonavir), which is used to treat mild-to-moderate COVID-19. Commercially insured people may be eligible for a $0 copay, with a maximum benefit of $1,500. Patients whose insurance companies apply accumulator or maximizer programs are not eligible for the copay program.

Patients with migraine can a set up a virtual appointment with a doctor through UpScript for $35, as well as an in-person visit through Zocdoc.

Pfizer markets several therapies for migraine, including including Zavzpret (zavegepant) to treat acute migraine attacks in adults. It is available as a nasal spray. Pfizer offers a $0 copay program for a 30-day supply. NurtecODT is another Pfizer medication for migraine that is offered with a $0 copay and a maximum annual benefit of $7,000. The terms for both products indicate that patients whose insurance companies apply accumulator or maximizer programs are not eligible for the copay program.

To prevent respiratory syncytial virus (RSV), Pfizer markets Abrysvo for those 60 years of age and older and for women are pregnant to prevent RSV in infants. Pfizer recently announced data for Abrysvo in immunocompromised adults, which showed that the vaccine was well-tolerated and generated strong neutralizing responses after a single dose in those 18 years of age and older.

Pfizer and BioNTech are developing a combination vaccine against influenza and COVID-19, and the companies recently announced that a trial met one of its two primary immunogenicity objectives. The combination candidate consists of Pfizer’s mRNA-based influenza vaccine candidate with the companies’ licensed COVID-19 vaccine. The trial did not meet the objectives of non-inferiority against the influenza B strain despite, but did obtain higher influenza A responses and comparable COVID-19 responses versus the comparator vaccines.